A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
FDA approves Spravato as the first monotherapy for adults with major depressive disorder unresponsive to two oral ...
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...